Section 3.2.P.2 is where an applicant explains why the medicine is formulated, manufactured and packaged the way it is. Written well, it turns a set of specifications into a reasoned control strategy. Written poorly, it invites the questions that lengthen assessment.
What the section must cover
The CTD structure for pharmaceutical development, guided by ICH Q8(R2), asks for a coherent account of:
- Components of the drug product (3.2.P.2.1): the drug substance properties that can influence performance, such as solubility, particle size and polymorphism, and the choice and function of each excipient.
- The drug product (3.2.P.2.2): formulation development, any overages, and the physicochemical and biological properties relevant to performance, such as dissolution.
- Manufacturing process development (3.2.P.2.3): why the process was selected and how critical process parameters were identified.
- Container closure system (3.2.P.2.4): suitability for storage, transport and use.
- Microbiological attributes (3.2.P.2.5) and compatibility (3.2.P.2.6) with diluents or dosing devices where relevant.
From QTPP to control strategy
ICH Q8(R2) encourages a structured approach: define a quality target product profile (QTPP), identify the critical quality attributes (CQAs) that deliver it, and link material attributes and process parameters to those CQAs through risk assessment and experimentation. Applicants do not have to claim a design space, but even a traditional development package is stronger when it shows this logic explicitly.
The section should make clear how development findings justify the final specifications in 3.2.P.5 and the in-process controls in 3.2.P.3. Assessors look for that thread.
Common weaknesses
- Development reports summarised so briefly that the rationale for key choices is lost.
- Dissolution methods presented without evidence of discriminatory power.
- Clinical and commercial formulations that differ, without a bridging rationale.
- For generics, too little comparison with the reference product’s characteristics.
- Process changes during development that are not connected to batch data.
Looking ahead
The draft ICH M4Q(R2) revision proposes giving development and control strategy a more prominent and structured place in the dossier. Companies that already write 3.2.P.2 around QTPP, CQAs and control strategy will find the transition easier.
How PQRA helps
PQRA reviews and authors pharmaceutical development sections, linking development data to specifications and process controls so that the dossier presents a clear, defensible control strategy.
Contact PQRA to discuss your next dossier.


No responses yet